Japan Alzheimer’s Disease Drugs Market Report 2022 to 2030

Japan Alzheimer’s Disease Drugs Market Analysis

$ 3999

Japan's Alzheimer’s disease drugs market was valued at $958 Mn in 2022 and is estimated to expand at a CAGR of 8.92% from 2022-30 and will reach $1899 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson., Novartis AG, Pfizer, Takeda Pharmaceutical, Chugai Pharmaceutical, Astellas Pharma, Otsuka Holdings Co, Shionogi & Co among others.

ID: IN10JPPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Nandini Shah

Buy Now

Japan Alzheimer’s Disease Drugs Market Executive Summary

The Japan Alzheimer’s Disease Drugs market was valued at $958 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.92% from 2022 to 2030 and will reach $1899 Mn in 2030. Degeneration of brain nerve cells is a hallmark of Alzheimer's disease. It results in a decline in cognitive abilities such as memory, language, thinking, and behavior. Alzheimer's disease symptoms include depression, memory loss, lack of inhibitions, and problems thinking and reasoning. It is normally diagnosed through physical examinations, blood tests, brain imaging, mental status exams, and neuropsychological testing. Depending on the results, doctors prescribe different medications to reduce symptoms. Neurotransmitters, which are chemicals that convey messages between nerve cells in the brain, are affected by drugs for Alzheimer's disease.

More than 4.6 million people in Japan are affected by dementia. And it is predicted that as the population ages, this number will increase dramatically. Given that dementia affects at least 44 million individuals worldwide, the condition is a global health emergency that requires attention. Alzheimer's disease is a diagnosis that alters the lives of the patient, as well as their family and friends, but there is support and information available. Nobody has to deal with dementia or Alzheimer's alone.

japan alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

As the population in Japan continues to age, the incidence of Alzheimer's disease is expected to increase. This is a major driver of growth in the Alzheimer's drugs market in Japan. There has been a growing awareness of Alzheimer's disease in Japan, which has led to an increase in the number of diagnoses. This has resulted in an increased demand for Alzheimer's drugs. The Japanese government has taken steps to support the development of new Alzheimer's drugs, including providing funding for research and development. This has led to the introduction of new and more effective treatments. As healthcare expenditure in Japan continues to grow, more resources are being devoted to treating Alzheimer's disease. This has led to an increased demand for Alzheimer's drugs. Pharmaceutical companies are continuing to invest in the development of new Alzheimer's drugs, which are expected to drive growth in the market in the coming years.

Market Restraints

There is significant price pressure on Alzheimer's drugs in Japan, with the government and insurance companies seeking to reduce healthcare costs. This has resulted in lower prices for drugs and reduced profitability for pharmaceutical companies. There is strong competition from generic versions of Alzheimer's drugs in Japan, which can be significantly cheaper than branded drugs. This has led to a decrease in market share and revenue for some pharmaceutical companies. The regulatory environment in Japan can be challenging for pharmaceutical companies, with long approval times and strict requirements for clinical trials. This can slow down the development and launch of new Alzheimer's drugs. Despite significant investment in research and development, there is still a lack of effective treatments for Alzheimer's disease. Many drugs have shown only limited efficacy in clinical trials, which can be discouraging for pharmaceutical companies and investors.

Competitive Landscape

Key Players

Kyowa Kirin
Daiichi Sankyo Company
Eisai Co.
Eli Lilly and Company
H. Lundbeck A/S
Johnson and Johnson
F. Hoffmann-La Roche AG
Merck & Co.
Novartis AG
Pfizer
Takeda Pharmaceutical
Chugai Pharmaceutical
Astellas Pharma
Otsuka Holdings Co
Shionogi & Co

Healthcare Policies and Regulatory Landscape

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is responsible for the approval of drugs, medical devices, and regenerative medicine products. The PMDA assesses the safety, efficacy, and quality of new drugs before they can be marketed in Japan. In addition, the Japanese government has implemented a Health Technology Assessment (HTA) system to evaluate the cost-effectiveness of new drugs and medical devices. The HTA system assesses the clinical benefits, economic impact, and social implications of new drugs before they can be approved for reimbursement by the government. In terms of Alzheimer's disease, the Japanese government has implemented policies to encourage the development and approval of new drugs. For example, the Japanese government has implemented a fast-track approval system for innovative drugs, which can expedite the approval process for drugs that meet certain criteria.

Reimbursement Scenario

In Japan, the cost of healthcare is covered by the National Health Insurance (NHI) system. The NHI covers the cost of medical services and prescription drugs, including Alzheimer's drugs, for all residents of Japan. Under the NHI system, patients are required to pay a portion of the cost of treatment, known as the "co-payment." The co-payment for Alzheimer's drugs in Japan is typically around 30% of the cost of the drug, with the remaining 70% covered by the NHI. In addition to the NHI, there are other public and private insurance programs in Japan that provide coverage for healthcare costs, including Alzheimer's drugs. For example, the Long-term Care Insurance system provides coverage for the cost of long-term care for elderly individuals, including those with Alzheimer's disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Billion)

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
Combination Drugs
Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Billion)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Route of Administration

Oral
Transdermal
Intravenous

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.